LT3 Stock Chart & Stats
€35.43
€1.29(3.78%)
At close: 4:00 PM EDT
€35.43
€1.29(3.78%)
Day’s Range― - ―
52-Week Range€13.10 - €44.33
Previous CloseN/A
Volume0.00
Average Volume (3M)35.00
Market Cap
€2.30B
Enterprise Value€2.37K
Total Cash (Recent Filing)€94.57M
Total Debt (Recent Filing)€20.07M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 10, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding53,761,513
10 Day Avg. Volume0
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)11.70
Price to Sales (P/S)6.69
P/FCF Ratio-513.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€47.86Price Target Upside35.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.38
Revenue Forecast (FY)€239.79M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And GuidanceSustained double-digit growth and a raised annual outlook indicate strong demand for peripheral nerve products. Continued execution could improve operating leverage and reinforce AxoGen’s market position over the next several quarters.
Avance Adoption And Market ExpansionAvance adoption and rapid Breast-market expansion broaden the company’s growth platform beyond established procedures. Increasing programs, surgeons and account productivity can support recurring procedure-driven demand and strengthen competitive reach.
Balance Sheet And Cash GenerationLow leverage, a sizable equity cushion and improving positive cash flow provide financial flexibility while the company funds commercial and clinical initiatives. This reduces balance-sheet risk and supports investment in longer-term growth.
Bears Say
Persistent GAAP LossesOngoing GAAP losses mean revenue growth has not yet translated into durable bottom-line profitability. If losses persist, they could constrain retained capital, weaken shareholder returns and limit the benefits of the company’s expanding scale.
Gross Margin PressureThe faster-growing product mix currently carries higher production costs, creating a structural risk to margin expansion. Pricing and manufacturing actions may help, but management expects the effect to take time and revised 2026 margin guidance to at least 73%.
Rising Operating ExpensesCommercial expansion and higher corporate spending are absorbing more of the company’s gross profit, limiting near-term operating leverage. These investments may support future growth, but returns depend on converting expanded coverage and sales capacity into profitable volume.
AxoGen News
LT3 FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was €13.10 and its highest was €44.33 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is €2.30B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Nov 10, 2026 which is in 75 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Jul 29, 2026. The company reported €0.103 earnings per share for the quarter, missing the consensus estimate of €0.104 by >-€0.001.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen does not currently pay dividends.
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.11.
How many shares outstanding does AxoGen have?
AxoGen has 53,761,513 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of €0.103 in its last earnings report, missing expectations of €0.104. Following the earnings report the stock price went down -0.367%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in DE:LT3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€47.86 (35.09% Upside)
€47.86 (35.09% Upside)
Blogger Sentiment
Bullish
DE:LT3 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
198.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.39%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
LT3 Company Deck
LT3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: robust revenue growth (Q2 +23.1%), a pronounced acceleration in the Breast market (YTD +47%) that materially expanded Avance volume and adoption, growing active surgeon and account metrics, cash balance strength and raised revenue guidance. Offsetting this optimism are near-term margin pressures driven by an accelerated shift in product mix toward longer, higher-cost Avance grafts, increased operating expenses tied to commercial investment, and pending payer decisions (notably Aetna) that could further accelerate adoption but remain unquantified. Management outlined actionable plans (pricing and production efficiency initiatives) but emphasized these will take time to influence 2026 results. Overall, positives (strong top-line, guidance raise, evidence progress, healthy cash position and commercial momentum) outweigh the manageable operational and margin challenges disclosed.View all DE:LT3 earnings summariesLT3 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€47.86
▲(35.09% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month











